-
公开(公告)号：US10322108B2
公开(公告)日：2019-06-18
申请号：US15541137
申请日：2016-01-22
发明人： Hai Xue , Tao Zhao , Mi Young Cha , Maengsup Kim
IPC分类号： A61K31/404 , C07D209/10 , C07D209/08 , A61K31/03 , A61K31/192 , A61K31/196
摘要： Disclosed are a compound, a stereisomer and a tautomer thereof, a pharmaceutically acceptable salt thereof, and a solvate or a prodrug thereof, which can be used for preventing or treating a RORγ mediated disease. The compound has the structural formula (I).
-
公开(公告)号：US09840517B2
公开(公告)日：2017-12-12
申请号：US15022248
申请日：2014-09-18
发明人： Jinming Liu , Mi Young Cha , Gong Li , Zhanmei Li , Hongjuan Qiu , Maengsup Kim
IPC分类号： C07D495/04 , A61K31/519 , A61K31/53 , A61K31/5377 , C07D487/04 , C07D491/048 , A61K45/06 , C07D519/00
CPC分类号： C07D495/04 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K45/06 , C07D487/04 , C07D491/048 , C07D519/00 , A61K2300/00
摘要： The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).
-
3.发明申请公开(公告)号：US20160340422A1
公开(公告)日：2016-11-24
申请号：US15114006
申请日：2015-01-28
发明人： Guoqiang Chen , Jiawang Liu , Nanmeng Song , Yaping Yang , Mi Young Cha
IPC分类号： C07K16/24 , C07K14/705
CPC分类号： C07K16/244 , A61K38/00 , A61K39/00 , C07K14/7051 , C07K14/70521 , C07K16/24 , C07K2317/24 , C07K2317/92 , C07K2319/00
摘要： The present invention provides a bifunctional fusion protein comprising the extracellular region of CTLA4 and an anti-IL-17 antibody, a gene encoding the protein, a vector comprising the gene, a host cell comprising the vector, and a pharmaceutical composition containing the protein.
摘要翻译： 本发明提供了包含CTLA4的细胞外区域和抗IL-17抗体的双功能融合蛋白，编码该蛋白质的基因，包含该基因的载体，包含载体的宿主细胞和含有该蛋白质的药物组合物。
-
公开(公告)号：US11498977B2
公开(公告)日：2022-11-15
申请号：US16337854
申请日：2017-09-28
发明人： Jiawang Liu , Nanmeng Song , Dongge Yang , Yaping Yang , Maengsup Kim
摘要： The present invention provides a method for production of stable and highly specific heterodimeric immunoglobulin constructs, e.g., bispecific antibodies, retaining desirable properties of native IgG and lacking undesirable heavy chain-light chain mispairing, that can simultaneously bind two target molecules and are more potent in the treatment of complex diseases.
-
公开(公告)号：US11319378B2
公开(公告)日：2022-05-03
申请号：US16461646
申请日：2017-11-16
发明人： Jiawang Liu , Nanmeng Song , Yaping Yang , Maengsup Kim
摘要： Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. Specifically, provided are a highly stable anti-PD-1/anti-HER2 heterodimeric bispecific antibody having characteristics of a natural IgG and having no mismatched heavy chain and light chain, and a method of preparing the same. The bispecific antibody may bind to both of two kinds of target molecules, and thus may be more effective in treating complex diseases.
-
公开(公告)号：US10988482B2
公开(公告)日：2021-04-27
申请号：US15751766
申请日：2015-08-13
发明人： Baoyu Xue , Runa Zheng , Mi Young Cha , Maengsup Kim
IPC分类号： C07D495/04 , C07D487/04 , C07D491/048 , A61K45/06
摘要： The present invention relates to a compound inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (particularly humans). The compound has a structural formula I.
-
公开(公告)号：US20180051036A1
公开(公告)日：2018-02-22
申请号：US15799315
申请日：2017-10-31
发明人： Jinming LIU , Mi Young CHA , Gong LI , Zhanmei LI , Hongjuan QIU , Maengsup KIM
IPC分类号： C07D495/04 , C07D519/00 , C07D491/048 , C07D487/04 , A61K31/5377 , A61K31/53 , A61K45/06 , A61K31/519
CPC分类号： C07D495/04 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K45/06 , C07D487/04 , C07D491/048 , C07D519/00 , A61K2300/00
摘要： The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).
-
公开(公告)号：US20170368028A1
公开(公告)日：2017-12-28
申请号：US15541137
申请日：2016-01-22
发明人： Hai Xue , Tao Zhao , Mi Young Cha , Maengsup Kim
IPC分类号： A61K31/404 , A61K31/196 , A61K31/03 , A61K31/192 , C07D209/10 , C07D209/08
CPC分类号： A61K31/404 , A61K31/03 , A61K31/192 , A61K31/196 , C07D209/08 , C07D209/10 , Y02A50/409
摘要： Disclosed are a compound, a stereisomer and a tautomer thereof, a pharmaceutically acceptable salt thereof, and a solvate or a prodrug thereof, which can be used for preventing or treating a RORγ mediated disease. The compound has the structural formula (I).
-
9.发明申请PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING INTERFERON ALPHA CONJUGATE 有权用于治疗癌症的药物组合物，包括干扰素ALPHA联合公开(公告)号：US20140219961A1
公开(公告)日：2014-08-07
申请号：US14342715
申请日：2012-09-05
申请人： Sung Youb Jung , Young Eun Woo , Se Young Lim , In Young Choi , Jae Ho Lee , Se Chang Kwon , Sung Hwan Moon , Jiawang Liu
发明人： Sung Youb Jung , Young Eun Woo , Se Young Lim , In Young Choi , Jae Ho Lee , Se Chang Kwon , Sung Hwan Moon , Jiawang Liu
IPC分类号： A61K47/48 , A61K31/7068 , A61K38/21
CPC分类号： A61K47/642 , A61K9/0019 , A61K31/7068 , A61K38/212 , A61K47/60 , A61K47/68
摘要： A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency. Co-administration of an anti-cancer agent and the interferon alpha conjugate having excellent anti-cancer activity reduces administration dose of anti-cancer agent so as to reduce side effects of anti-cancer agent and increase treatment compliance of patient.
摘要翻译： 预防或治疗癌症的方法包括施用包含干扰素α或其聚合物缀合物的抗癌药物组合物。 药物组合物可与抗癌剂共同施用。 干扰素α缀合物显示比常规干扰素α更长的体内半衰期和更优异的抗癌活性，特别是其与抗癌药如吉西他滨的共同给药对癌细胞具有协同抑制作用 生长和增殖，以显示出非常优异的抗癌活性。 此外，抗癌药物组合物具有优异的体内半衰期和抗癌活性，从而大大降低给药频率。 共同施用抗癌剂和具有优异抗癌活性的干扰素α缀合物降低了抗癌剂的施用剂量，从而降低了抗癌剂的副作用并增加了患者的治疗依从性。
-
公开(公告)号：US20220010006A1
公开(公告)日：2022-01-13
申请号：US17290480
申请日：2019-11-05
发明人： Jiawang LIU , Yaping YANG , Nanmeng SONG , Wenchu XIAO , Chulwoong CHUNG , Maengsup KIM
摘要： Provided are an anti-TNFα/anti IL-17A natural antibody structure-like heterodimer form of a bispecific antibody and a preparation method therefor, wherein the antibody can bind two target molecules simultaneously, and can be used for treating complex diseases.
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.02 秒)
